SPRO
Spero Therapeutics Inc
1.20$
-5.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +70.3% | -8.1% | -10.6% | -9.8% | -18.2% | -29.7% | -20.1% | -12.8% | +27.2% | -14.4% | -10.6% | |
| – | +28.4% | +6.8% | -12.8% | +7.7% | -18.5% | -30.4% | -20.5% | -11.9% | +28.6% | -14.4% | -10.5% | |
| – | -18.6% | +7.8% | -22.8% | +20.1% | -30.7% | -7.6% | -36.2% | +55.9% | -17.2% | +39.4% | -9.5% | |
| – | -18.6% | +7.8% | -22.8% | +20.1% | -30.7% | -7.6% | -36.2% | +55.9% | -17.2% | +39.4% | -9.5% | |
| – | +1,596.1% | +6.9% | -6.4% | +5.0% | -1.5% | -53.7% | +0.7% | -89.9% | +932.4% | -99.8% | -43.2% | |
| – | – | +0.0% | – | – | – | – | – | – | – | – | – | |
| – | +41.4% | -5.4% | -2.9% | +0.4% | -7.5% | -31.9% | -33.3% | -5.5% | -64.2% | -38.5% | +40.7% | |
| – | +45.9% | +12.6% | +9.1% | +7.6% | 0.0% | -40.6% | -48.7% | -8.7% | -35.0% | -38.1% | +53.5% | |
| – | +0.4% | +0.4% | +0.4% | +0.4% | +0.4% | +2.8% | +2.7% | +3.0% | +3.0% | +0.6% | +1.7% | |
| – | +24.9% | +122.5% | -12.1% | +125.9% | +20.0% | -75.8% | -55.8% | +78.8% | -50.3% | -68.7% | -28.6% | |
| – | +99.0% | -10.0% | -16.4% | -18.6% | -29.6% | -26.7% | -2.9% | -19.3% | +122.8% | -10.3% | -16.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.8% | +0.8% | +0.8% | +0.3% | -0.2% | +2.5% | +1.2% | +0.5% | +5.5% | -3.5% | +1.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.